• Indiva (NDVA) has reseived a sales license for its edibles, extracts and topicals from Health Canada
  • The company intends to commence immediate shipping to wholesalers in a variety of provinces
  • Indiva looks to satisfy non-smoking customers with alternative products
  • Shares in Indiva are currently up 10% to $0.28, with a market cap of $22.99 million

Indiva (NDVA) has received a sales license from Health Canada for its edibles, extracts and topicals, which will enable the company to deliver its non-smokable products to Canadian consumers.

Indiva intends to immediately commence shipping to wholesalers in Ontario, Nova Scotia, Alberta, Saskatchewan, Manitoba and British Columbia, with initial batches to primarily include the Bhang Milk and Dark Chocolate bars, which contain 10mg of THC each.

The company’s Bhang CBD Chocolate Bars will be available later this year.

“To say we are excited to receive this sales licence is an understatement. This sales licence is transformational for Indiva as it allows us to enter new markets and product categories and distribute products nationally,” said Indiva President and CEO, Niel Marotta.

“We believe that delivering Canadians truly exceptional and innovative products is our calling and through that passionate pursuit, we can normalize cannabis use. There are millions of Canadians who would like to consume cannabis, but prefer to avoid smoking. Indiva intends to be the solution for those consumers by providing chocolate, sugar, salt, fruit chews and more. We look forward to fulfilling existing purchase orders and having our products available to consumers, on shelves and online, at the earliest opportunity.”

The announcement comes after earlier news that Indiva had delivered its first batch of products to the Société québécoise du cannabis – a subsidiary of the government-owned SAQ – which holds a legislative monopoly on the sale of recreational cannabis within Quebec.

The shipment included Indiva’s White Russian and Jack Herer dry flowers and pre-rolls.

The company’s shares are currently up 10% to $0.28, with a market cap of $22.99 million.

More From The Market Online
Cannabis Report image of farmed cannabis plants

The Market Online’s Weekly Cannabis Report – July 26, 2024

Tilray Oral Solution THC10:CBD10 cannabis extract, aka Tilray Solução Oral THC10:CBD10, has been approved for medical use in Portugal.
medical branch logo

Tilray approved for third medical cannabis product in Portugal

Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.